Drug Profile


Alternative Names: ABT-RTA-408; RTA-408

Latest Information Update: 15 Feb 2016

Price : $50

At a glance

  • Originator Dartmouth College; University of Texas M. D. Anderson Cancer Center
  • Developer AbbVie; Reata Pharmaceuticals
  • Class Anti-inflammatories; Antineoplastics; Small molecules; Triterpenes
  • Mechanism of Action NF E2 related factor 2 stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Friedreich's ataxia; Mitochondrial disorders; Ocular inflammation; Ocular pain
  • Phase I/II Malignant melanoma
  • Phase I Non-small cell lung cancer
  • Discontinued Duchenne muscular dystrophy; Radiation-induced skin damage

Most Recent Events

  • 12 Oct 2015 Discontinued - Phase-II for Radiation-induced skin damage in USA (Topical)
  • 12 Oct 2015 Discontinued - Preclinical for Duchenne muscular dystrophy in USA (unspecified route)
  • 01 Oct 2015 Reata Pharmaceuticals completes the DISCOVER trial in Non-small cell lung cancer (Late-stage disease, Second-line therapy or greater)and Malignant melanoma (Late-stage disease, Second-line therapy or greater) in USA (NCT02029729)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top